The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Beta Blockers and Breast Cancer Mortality: A Population- Based Study
Abstract
Purpose: Preclinical studies have demonstrated that antagonism of β 2 -adrenergic signaling inhibits several pathways necessary for breast tumor progression and metastasis. A series of population-based observational studies were conducted to examine associations between beta blocker use and breast tumor characteristics at diagnosis or breast cancer–specific mortality. Patients and Methods: Linked national cancer registry and prescription dispensing data were used to identify women with a diagnosis of stage I to IV invasive breast cancer between January 1, 2001, and December 31, 2006. Women taking propranolol (β 1 /β 2 antagonist; n = 70) or atenolol (β 1 antagonist; n = 525), in the year before breast cancer diagnosis were matched (1:2) to women not taking a beta blocker (n = 4,738). Associations between use of propranolol or atenolol and risk of local tumor invasion at diagnosis (T4 tumor), nodal or metastatic involvement at diagnosis (N2/N3/M1 tumor), and time to breast cancer–specific mortality were assessed. Results: Propranolol users were significantly less likely to present with a T4 (odds ratio [OR], 0.24, 95% CI, 0.07 to 0.85) or N2/N3/M1 (OR, 0.20; 95% CI, 0.04 to 0.88) tumor compared with matched nonusers. The cumulative probability of breast cancer–specific mortality was significantly lower for propranolol users compared with matched nonusers (hazard ratio, 0.19; 95% CI, 0.06 to 0.60). There was no difference in T4 or N2/N3/M1 tumor incidence or breast cancer–specific mortality between atenolol users and matched nonusers. Conclusion: The results provide evidence in humans to support preclinical observations suggesting that inhibiting the β 2 -adrenergic signaling pathway can reduce breast cancer progression and mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
American Joint Committee on Cancer (2002) · Springer eBooks · doi:10.1007/978-1-4757-3656-4 · Cited by 6,379
The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited
Fidler, I. J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1098 · Cited by 4,686 · cited 1×
“invasion and migration, key steps in tumor progression and the pathogenesis of metastasis.(6-15) Norepi-”
BackgroundAJCC Cancer Staging Manual. 6th ed
Greene, F., Page, D., Id, F., Fritz, J., Balch, C., & Haller, D. (2002) · Cited by 2,324
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
Thaker, P. H., Han, L. Y., Kamat, A. A., Arevalo, J. M., Takahashi, R., Lu, C., Jennings, N. B., Armaiz-Pena, G., Bankson, J. A., Ravoori, M., et al. (2006) · Nature Medicine · doi:10.1038/nm1447 · Cited by 1,320
The influence of bio-behavioural factors on tumour biology: pathways and mechanisms
Antoni, M. H., Lutgendorf, S. K., Cole, S. W., Dhabhar, F. S., Sephton, S. E., McDonald, P. G., Stefanek, M., & Sood, A. K. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1820 · Cited by 981
The sympathetic nervous system induces a metastatic switch in primary breast cancer
Sloan, E. K., Priceman, S. J., Cox, B. F., Yu, S., Pimentel, M. A., Tangkanangnukul, V., Arevalo, J. M. G., Morizono, K., Karanikolas, B. D. W., Wu, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0522 · Cited by 930 · cited 4×
“receptor, and are inhibited by 2 receptor antagonists (eg, propranolol).(8-12,15,16,20) Similar inhibitory effects are not observed with the use of 1 selective antagonists (eg, atenolol).”
BackgroundResultInfluentialSchneeweiss, S. (2001) · American Journal of Epidemiology · doi:10.1093/aje/154.9.854 · Cited by 711
Macleod, U., Mitchell, E. D., Burgess, C., Macdonald, S., & Ramirez, A. J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605398 · Cited by 525
Factors predicting delayed presentation of symptomatic breast cancer: a systematic review
Ramirez, A., Westcombe, A., Burgess, C., Sutton, S., Littlejohns, P., & Richards, M. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02142-x · Cited by 493
Cited by
Autonomic nerve development contributes to prostate cancer progression
Magnon, C., Hall, S. J., Lin, J., Xue, X., Gerber, L., Freedland, S. J., & Frenette, P. S. (2013) · Science · doi:10.1126/science.1236361 · Cited by 1,287
Mehta, L. S., Watson, K. E., Barac, A., Beckie, T. M., Bittner, V., Cruz-Flores, S., Dent, S., Kondapalli, L., Ky, B., Okwuosa, T., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000556 · Cited by 848
Molecular Pathways: Beta-Adrenergic Signaling in Cancer
Cole, S. W., & Sood, A. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0641 · Cited by 681
Sympathetic nervous system regulation of the tumour microenvironment
Cole, S. W., Nagaraja, A. S., Lutgendorf, S. K., Green, P. A., & Sood, A. K. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3978 · Cited by 576
Perioperative events influence cancer recurrence risk after surgery
Hiller, J. G., Perry, N. J., Poulogiannis, G., Riedel, B., & Sloan, E. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.194 · Cited by 556
Metadata
- Authors
- Barron, T. I., Connolly, R. M., Sharp, L., Bennett, K., & Visvanathan, K.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-07-01
- Volume
- 29
- Issue
- 19
- Pages
- 2635-2644
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2139731996
- Cited by
- 529
- References
- 32
- FWCI
- 23.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beta Blockers and Breast Cancer Mortality: A Population- Based Study. https://app.cochat.ai/papers/10.1200/jco.2010.33.5422
- The paper
- Barron, T. I., Connolly, R. M., Sharp, L., Bennett, K., & Visvanathan, K. (2011). Beta Blockers and Breast Cancer Mortality: A Population- Based Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.33.5422
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.